| Scientific articles | |||
---|---|---|---|---|
 | In English, n = 114 | In Chinese, n = 75 | Total, N = 189 | % |
Journal type | Â | Â | Â | Â |
 General | 101 | 16 | 117 | 61.9% |
 Human | 11 | 59 | 70 | 37.0% |
 Animal | 2 | 0 | 2 | 1.1% |
Sector | Â | Â | Â | Â |
 Human | 56 | 61 | 117 | 61.9% |
 Animal | 36 | 4 | 40 | 21.2% |
 General | 22 | 10 | 32 | 16.9% |
Setting | Â | Â | Â | Â |
 Lab-based | 86 | 49 | 135 | 71.4% |
 Clinical/facility-based | 15 | 8 | 23 | 12.2% |
 Urban community based | 1 | 3 | 4 | 2.1% |
 Urban-Rural (mixed) | 11 | 14 | 25 | 13.2% |
 Occupational | 0 | 0 | 0 | 0.0% |
 Rural community based | 1 | 1 | 2 | 1.1% |
Species | Â | Â | Â | Â |
 Pathogen | 59 | 37 | 96 | 50.8% |
 Human | 30 | 29 | 59 | 31.2% |
 Dog | 11 | 3 | 14 | 7.4% |
 Multiple animals | 14 | 6 | 20 | 10.6% |
Immuno-genetics | 19 | 11 | 30 | Â |
Basic epidemiology | 36 | 27 | 63 | 100.0% |
 Case studies or outbreak reports in humans and animals | 17 | 4 | 21 | 33.3% |
 Seroprevalence in animals | 3 | 4 | 7 | 11.1% |
 Surveillance data and risk factors | 6 | 14 | 20 | 31.7% |
 *PEP patients’ analysis | 9 | 1 | 10 | 15.9% |
 Costs of treatment | 0 | 1 | 1 | 1.6% |
 Level of awareness in public and health care workers | 1 | 3 | 4 | 6.3% |
Vaccines and diagnostics development | 26 | 10 | 36 | Â |
Virology - Molecular epidemiology | 30 | 20 | 50 | 100.0% |
 Virology | 11 | 15 | 26 | 52.0% |
 Molecular epidemiology | 14 | 3 | 17 | 34.0% |
 Modeling - dynamics | 5 | 2 | 7 | 14.0% |
Review | 4 | 6 | 10 | Â |
Evidence based policies and systems analysis | 0 | 0 | 0 | Â |
Evidence-based practices or new interventions | Â | Â | Â | Â |
 Dogs management | 0 | 0 | 0 |  |
 Caracteristics of dogs: pop. estimates/of owned | 0 | 0 | 0 |  |
 Development of Monitoring and Evaluation tools | 0 | 0 | 0 |  |
Evidence-based advocacy | Â | Â | Â | Â |
 Disease burden - incidence | 0 | 0 | 0 |  |
 Cost of illness | 0 | 0 | 0 |  |